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Background: Epithelial-Mesenchymal Transition (EMT) is a transient and reversible (Mesenchymal-Epithelial
Transition or MET) process by which epithelial cells acquire mesenchymal cell characteristics including reduced
intercellular adhesion and increased cell motility. While EMT/MET has long been recognized as an essential
component of early embryonic development, there is a growing body of evidence indicating that EMT/MET is also
a key component of ovarian cancer (OC) metastasis. Recent findings have implicated members of the miR-200
family of microRNAs (miRNAs) in this process.
Methods: Individual members of the miR-200 family of miRNAs were transiently over expressed in metastatic
(mesenchymal-like) OC cell lines. Changes in morphology, molecular profiles and drug sensitivity were monitored
relative to cells transfected with a negative control.
Results: Morphological hallmarks of MET were detected in cells transfected with all miR-200 family members. Gene
expression profiling demonstrated up regulation of epithelial biomarkers and down regulation of mesenchymal
biomarkers in transfected cells although significant variation in molecular response and drug sensitivity was
associated with different members of the miR-200 family.
Conclusions: Our results indicate that although ectopic overexpression of all members of the miR-200 family in
mesenchymal-like OC cells results in morphological changes characteristic of MET, the underlying molecular
changes and induced drug sensitivities are highly variable and correlated with sequence variation within the seed
and non-seed regions of individual family members.
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Ovarian cancer is the most lethal of all gynecologic can-
cers [1]. The majority of OC related deaths is attribut-
able to the spread of cancer cells from the primary
tumor to metastatic sites throughout the abdominal
cavity [2]. During early stages of metastasis, a subset of* Correspondence: john.mcdonald@biology.gatech.edu
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stated.primary epithelial tumor cells undergo epithelial-to-
mesenchymal transition (EMT), whereby intercellular
adhesion complexes are disrupted, the characteristic
apico-basal polarity of the cells is lost and cells acquire
elevated levels of motility, invasiveness and resistance to
standard chemotherapeutic treatments [3-5]. Subsequent
to attachment to secondary sites, metastasizing cells
undergo a complementary mesenchymal-to-epithelial
transition (MET) whereby the metastatic cells reacquire
epithelial morphologies and other features characteristic
of the primary tumor cells [6]. Because of the highLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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cancers, considerable effort is currently being directed to-
wards the development of new classes of agents that may
reduce the spread of cancer cells by inducing MET [7].
We have previously shown that mesenchymal-like
OC cells undergo MET in response to ectopic over-
expression of miR-429, a member of the miR-200 family
of miRNAs [8]. This finding is consistent with earlier
observations implicating members of the miR-200 family
of miRNAs in MET [9,10]. In this paper we report the
results of a systematic examination of the effect of ec-
topic over expression of members of the miR-200 family
of miRNAs in OC mesenchymal-like cell lines. The
results indicate that although over expression of each
member of the miR-200 family induces significant changes
in many of the morphological and molecular hallmarks of
MET, significant differences exist among family members
in the expression of EMT/MET biomarkers and in induced
drug sensitivity. This functional variability is associated with
sequence variation mapping to both the seed and non-seed
regions of individual miRNAs.
Methods
Cell culture and miRNA transfection
HEY and HEY A8 ovarian cancer cell lines were pro-
vided by Gordon B. Mills (MD Anderson Cancer Center,
Houston, TX). SKOV-3 ovarian cancer cells were ob-
tained from the American Type Culture Collection
(ATCC, Manassas, VA). Cells were cultured in RPMI
1640 (Mediatech, Manassas, VA) supplemented with
10% FBS (Fetal Bovine Serum; Atlanta Biologicals,
Lawrenceville, GA) and 1% antibiotic-antimycotic solu-
tion (Mediatech-Cellgro, Manassas, VA). For miRNA
transfections, 6 × 104 cells were seeded per well in 24-
well plates. Cells at exponential phase of growth were
transfected with 30 nM miRNA purchased as Pre-miR
miRNA Precursors (Ambion, Austin, TX) using Lipofec-
tamine 2000 (Invitrogen, Carlsbad, CA) and according
to the manufacturer’s instructions. Cells were allowed to
grow for 48 hours before RNA isolation. Ambion Pre-
miR miRNA Precursor Negative Control was used as a
negative control (nc-miR).
Image capture and morphological assessment
Morphological changes were monitored using an Olympus
IX51 microscope (Olympus Optical, Melville, NY). The ef-
fect of treatment on cell morphology was objectively mea-
sured using CellProfiler cell-imaging software (2.1.0) [11].
Quantitative reverse transcription real-time PCR (qRT-PCR)
Total RNA was extracted from cells using the RNeasy
mini kit (Qiagen, Valencia, CA). RNA concentrations
were measured using a NanoDrop 1000 Spectrophotom-
eter V3.2 (NanoDrop, Wilmington, DE). Highly pureRNA samples (A260/A280 between 2.0 and 2.1) were
converted into first-strand cDNA with the Superscript
III First-strand Synthesis System (Invitrogen, Carlsbad,
CA). Real-time PCR analyses were performed using iQ
SYBR Green Supermix (Bio-Rad, Hercules, CA) on the
CFX96 real-time PCR system (Bio-Rad, Hercules, CA).
The primer sequences employed are as follows: KRT7
(keratin 7): forward 5′- GGACATCGAGATCGCCAC
CT-3′ and reverse 5′- ACCGCCACTGCTACTGCCA-
3′; KRT8 (keratin 8): forward 5′- CCGTGGTTGTGA
AGAAGATCG-3′ and reverse 5′-GCTGTTCACTTGG
GCAGGAC-3′; KRT18 (keratin 18): forward 5′-TGA
GACGTACAGTCCAGTCCTT-3′ and reverse 5′-GCT
CCATCTGTAGGGCGTAG-3′; GAPDH: forward 5′- TG
CACCACCAACTGCTTAGC -3′ and reverse 5′- GGC
ATGGACTGTGGTCATGA -3′. The primer sequences
for mesenchymal biomarker genes were described
previously [8]. The threshold cycle and ΔΔCt method
was used for calculating the relative amount of the tar-
get RNA. Expression values were normalized using
GAPDH as a reference gene.
Immunostaining
5 × 103 cells were cultured on eight well chamber slides.
Cells at exponential phase of growth were transfected as
indicated above. 48 hours after transfection, media was
removed and cells were fixed in 10% neutral buffered
formalin for 15 min. Cells were then washed, perme-
abilized with 0.5% Triton X-100 for 5 min, washed again
and blocked with 5% BSA (Bovine Serum Albumin) in
PBS for 1 hour. The slides were incubated with mouse
monoclonal primary antibodies against CDH1 (E-cadherin)
and FN1 (Fibronectin, 1:200; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) in 5% BSA for 1 hour at room
temperature. After washing, the slides were then incubated
with Alexa Fluor 488 Rabbit Anti-Mouse secondary
antibody (1:500, Molecular Probes, Inc., Eugene, OR) for 1
hour at room temperature. After a wash with PBS, counter-
staining was performed using DAPI (4′,6-diamidino-2-phe-
nylindole, 1:2000) in PBS for 30 min. Cells were then
mounted and expression status of protein biomarkers was
assessed using the Zeiss confocal microscope system
(Carl Zeiss, Jena, Germany).
Cisplatin sensitivity
Aliquots of cells were seeded in 96-well plates and
treated with nine concentrations of cisplatin ranging
from 0.1-50 μM. After 72 hours, TOX-8 reagent (Resazurin
based in vitro toxicology assay kit, Sigma-Aldrich, St Louis,
MO) was added to the wells and fluorescence was mea-
sured (λex = 560 nm, λem = 590 nm). Outlier values were
removed using Grubbs’ test. The ratio of the background-
subtracted fluorescence intensities of drug treated to un-
treated cultures was calculated in percentages across all
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regression of log-transformed data using a normalized
response-variable slope model with GraphPad Prism v.6
(GraphPad Software Inc., La Jolla, CA).
Statistical analysis
Statistical significance of differences in qRT-PCR experi-
ments between experimental and control samples was de-
termined using a two-tailed Student’s t-test. Significance of
differences in eccentricity profiles of experimental and
control samples was evaluated using Mann-Whitney U test.
Statistical significance of differences in mean IC50 values
among miRNA transfections was tested using analysis of
variance (ANOVA) and Tukey’s multiple comparison test
as a post-hoc test. All experiments were performed using at
least three biological replicates.Figure 1 Over expression of miR-429 induces morphological and mol
Representative phase contrast microscopy images of HEY A8 cells transfect
(iii) nc-miR and (iv) miR-429, 48 hours post transfection. Scale bars, 50 μm.
429 transfected groups (eccentricity: a score of 0 = circular shape, a score o
(SEM). Significance of differences between experimental and control sampl
127-258 cells analyzed per group). (C) Relative mRNA expression of represe
miR-429 transfection are normalized to negative control in each cell line an
in three technical replicates. Asterisks represent significant differences fromResults
MiR-429 is capable of inducing MET in multiple
mesenchymal-like OC cell lines
We have previously shown that exogenous over expres-
sion of miR-429 induces MET in a well-characterized
mesenchymal-like OC cell line (HEY) [8]. We were in-
terested in determining if this ability of miR-429 to in-
duce MET extends to other mesenchymal-like OC cell
lines as well. Consistent with our previous results, ex-
ogenous over expression of miR-429 in two additional
mesenchymal-like OC cell lines (HEY A8 [12] and
SKOV-3 [13]) was found to induce morphological and
molecular changes consistent with MET (Figure 1). Both
SKOV-3 and HEY A8 cells display a change from the
elongated shape characteristic of mesenchymal cells to
the more cuboidal shape characteristic of epithelial cellsecular changes consistent with the induction of MET. (A)
ed with (i) nc-miR and (ii) miR-429, and SKOV-3 cells transfected with
(B) The accumulation of rounded epithelial-like cells occurred in miR-
f 1 = linear shape). Values represent mean ± standard error of the mean
es is evaluated using Mann-Whitney U test (*P <0.05, **P <0.005, n =
ntative epithelial and mesenchymal biomarkers. Expression values in
d represent mean ± SEM of three biological replicates each performed
the negative control (*P <0.005, **P < 0.0005, Student’s t-test).
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was objectively validated using the CellProfiler cell image
analysis software [11]. Changes in expression of two epithe-
lial KRT8 and KRT18 and two mesenchymal [ZEB1 and
ZEB2 (zinc finger E-box binding homeobox 1 and 2)] mo-
lecular biomarkers were consistent with MET.
All members of the miR-200 family of miRNAs are capable
of inducing MET in OC mesenchymal-like cells
MiR-429 is a member of the miR-200 family of miRNAs
(Figure 2A). All members of the miR-200 family haveFigure 2 Over expression of the miR-200 family induces morphologic
sequence alignment of the miR-200 family. Alignment is performed using t
highlighted. (B) Representative phase contrast microscopy images of (i) HE
miR-200a, (iv) miR-141, (v) miR-200b, (vi) miR-200c, and (vii) miR-429, 48 h
rounded epithelial-like cells occurred in miR-200 family transfected cells. Va
Asterisks represent significant differences from the negative control (nc-miRpreviously been either directly or indirectly implicated
in EMT [9,10]. Having established that ectopic over
expression of miR-429 induces MET in a variety of
mesenchymal-like OC cell lines, we were interested in
determining if this MET-inducing potential extends to
other members of the miR-200 family as well.
The results presented in Figure 2 demonstrate that
over expression of all miR-200 family members results
in a significant change from the elongated, spindle-
shaped morphology of the mesenchymal-like cells to the
more rounded, cuboidal morphology characteristic ofal changes consistent with the induction of MET. (A) Multiple
he ClustalW2 program. Sequence differences relative to miR-429 are
Y cells (not transfected), HEY cells transfected with (ii) nc-miR, (iii)
ours post transfection. Scale bars, 50 μm. (C) The accumulation of
lues represent mean ± SEM (n = 124-211 cells analyzed per group).
) (*P <0.0001, NS = not significant, Mann-Whitney U test).
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was observed in cells treated with the negative control
(nc-miR).
The expression levels (qRT-PCR) of a series of previ-
ously established epithelial and mesenchymal biomarkers
[14] were monitored in HEY cells transfected with mem-
bers of the miR-200 family. Consistent with acquisition
of a more epithelial phenotype, expression levels of all of
the epithelial biomarkers (KRT8, KRT18, KRT7) were in-
creased after over expression of each member of the
miR-200 family (Figure 3). As expected, the mesenchy-
mal biomarkers ZEB1/ZEB2 displayed a general reduc-
tion in expression levels after over expression of each
member of the miR-200 family. The mesenchymal bio-
marker FN1 was also significantly down regulated in
cells transfected with miR200b, miR200c and miR429.
Human miRNAs are known to be capable of regulat-
ing expression of their target genes by modulating
mRNA levels and/or blocking translation [15]. Thus, to
further explore the inconsistent response of changes inFigure 3 Over-expression of the miR-200 family induces changes in b
expression of representative epithelial and mesenchymal biomarkers after o
values are normalized to nc-miR transfected cell and represent mean ± SEM
replicates. Asterisks represent significant differences from the negative control gFN1 RNA levels after transfection by individual members
of miR200 family, we additionally monitored expression
changes on the protein level by immunofluorescence stain-
ing. The epithelial biomarker, CDH1 [14,16], was included
in these assays as an additional control (Figure 4).
Consistent with the observed increase in expression
levels of each of the epithelial biomarkers monitored on
the RNA level, CDH1 protein was detected in all trans-
fected cells but was absent in un-transfected cells and in
cells transfected with the negative control. Interestingly,
levels of FN1 protein were generally consistent with
what was observed on the RNA level, i.e., protein levels
were significantly down regulated in cells transfected
by miR-200b, miR-200c or miR-429 but unchanged or
slightly up-regulated in cells transfected by miR-200a,
miR-141 (Figure 4). Collectively, these findings suggest
that FN1 is a regulatory target of miR-200b, miR-200c
and miR-429 but is not subject to regulation by miR-
200a and miR-141. In addition, since a change from a
mesenchymal to an epithelial phenotype was observed iniomarkers consistent with the induction of MET. Changes in the
ver-expression of miR-200 family members in HEY cells. Expression
of at least three biological replicates each performed in three technical
roup (*P <0.05, **P <0.005, ***P <0.0005, Student’s t-test).
Figure 4 Immunostaining of cells for CDH1 (A) and FN1 (B) proteins. (i) HEY cells (not transfected), HEY cells transfected with (ii) nc-miR,
(iii) miR-200a, (iv) miR-141, (v) miR-200b, (vi) miR-200c, and (vii) miR-429. DAPI was used to stain the cell nuclei. Scale bars, 50 μm.
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we conclude that FN1 is non-essential for MET in OC.
Previous studies indicate that the most functionally sig-
nificant component of miRNA/mRNA pairing involves the
miRNA “seed region”, i.e., nucleotides 2-8 on the 5′ end of
the miRNA [17]. Although all members of the miR-200
family are sequentially distinct, miR-200b, miR-200c and
miR-429 are sequentially identical within their respective
seed regions (Figure 2A). This identity may explain their
shared ability to down regulate FN1 when ectopically over
expressed in HEY cells. To further explore this possibility,
we utilized three miRNA target prediction algorithms (mi-
Randa [18], miRDB [19], and TargetScan [20]) to identify
members of the miR-200 family that are predicted to
directly target FN1 mRNA and the other biomarkers moni-
tored in our PCR experiments. The results, presented in
Table 1, indicate that all three algorithms predict the pres-
ence of binding sites in FN1 mRNA for miR-200b, miR-
200c and miR-429, but not for miR-200a, miR-141. These
computational predictions are consistent with our experi-
mental results and indicate that differences in target specifi-
city for FN1 mRNA between the miR-200 family members
accounts for the observed variation in regulation of FN1
expression.HEY cells transfected by miR-200 family members display
significant variation in sensitivity to cisplatin associated
with variation within the non-seed region of individual
miRNAs
Previous studies indicate that EMT is often associated
with decreased sensitivity of a variety of cancer cells to
chemotherapy [21-23]. Consistent with this observation,
OC cells undergoing EMT have been reported to display
a decreased sensitivity to platinum-based drugs, a fre-
quently employed first line therapeutic in the treatment
of OC [24,25]. Since EMT is reported to decrease the
sensitivity of OC epithelial cells to platinum-based
drugs, we were interested in determining if miR-induced
MET of mesenchymal-like OC cells would induce an op-
posite effect, i.e., be associated with an increased sensi-
tivity of OC cells to platinum-based drugs. To explore
this possibility, we monitored the drug susceptibility
(IC50) of HEY cells to cisplatin after miRNA-induced
MET relative to controls.
The results presented in Figure 5 demonstrate that
ectopic over expression of all members of the miR-200
family results in a significant increase in cisplatin sensi-
tivity relative to negative control. While notable vari-
ation was observed among cells transfected by different
Table 1 Prediction of miR-200 binding sites on FN1, ZEB1, ZEB2, KRT7, KRT8 and KRT18 mRNAs
miRNA miR-200b miR-200c miR-429 miR-200a miR-141
Prediction algorithm †A ¥B ǂC A B C A B C A B C A B C
FN1 2 2 1 2 2 1 2 2 1 0 0 0 0 0 0
ZEB1 5 6 5 5 6 5 5 6 5 3 3 3 3 3 3
ZEB2 6 5 6 6 5 6 6 5 6 3 4 2 3 4 2
KRT7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
KRT8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
KRT18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Only those genes predicted to be targeted by miR-200 family members were observed to be downregulated in cells in which they were ectopically overexpressed.
†A: miRanda (mirSVR ≤ -0.2), ¥B: miRDB, ǂC: TargetScan (conserved miRNA sites).
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variation was not statistically significant. Cells trans-
fected with miR-200b were significantly more sensitive
to cisplatin than those transfected with miR-429 (p <
0.05). Interestingly, these two miRNAs share identi-
cal seed regions suggesting that non-seed sequences
may be of significance in miR-200b induced drug
sensitivity.Figure 5 Effect of over expression of members of miR-200 family in H
mean ± SEM of at least 3 independent experiments with 3 replicated wells
ANOVA and Tukey’s multiple comparison test as a post-hoc test. Asterisks r
group, *P ≤0.05, **P ≤0.005. (B) Qualitative evaluation of cell viability in pre
transfected with different members of miR-200 family or nc-miR (crystal vioDiscussion
It is widely acknowledged that the metastatic spread of
cancer cells is responsible for most cancer related deaths
[26,27]. This is particularly true for OC where the pro-
spect of favorable outcome drops precipitously once
cancer cells migrate beyond the confines of the primary
tumor [28]. Since the EMT/MET process is believed to
play a central role in the metastasis of many cancers [29]EY cells on cisplatin sensitivity. (A) IC50 values are presented as
per drug concentration. Statistical analysis was performed using
epresent significant differences from the negative control (nc-miR)
sence of (i) 20 μM and (ii) 0 μM cisplatin in HEY cells alone or
let staining; Scale bars, 100 μm).
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cused on the discovery and development of reagents that
may intervene in this process for therapeutic benefit [7].
We previously demonstrated that ectopic over expres-
sion of miR-429, a member of the miR-200 family of
microRNAs, is sufficient to convert highly metastatic
OC mesenchymal-like cells to epithelial phenotype with
a concomitant reduction in invasive and migratory po-
tentials [8]. Prompted by these initial results, we were
interested in determining if the MET-inducing proper-
ties of miR-429 extended to other OC mesenchymal-like
cell lines and if other members of the miR-200 family
were also capable of exerting these potentially anti-
metastatic effects. Finally, since previous studies have
shown that OC cells induced to undergo EMT display
a significantly decreased sensitivity to platinum-based drugs
[24,25], we were interested to determine if miRNA-induced
reversal of the process (i.e., MET) might increase sensitivity
to these drugs thereby demonstrating an additional poten-
tial therapeutic benefit of these small regulatory RNAs.
Consistent with our earlier studies, we found that ec-
topic over expression of miR-429 in two additional OC
mesenchymal-like cell lines (SKOV-3 and HEY A8) re-
sults in morphological and molecular changes character-
istic of MET. Ectopic over expression of other members
of the miR-200 family in mesenchymal-like HEY cells
also induced morphological changes characteristic of
MET but underlying molecular changes were found to
be variable and attributable to sequence variation within
the seed region of individual family elements. Finally, we
tested the sensitivity of HEY cells to cisplatin after trans-
fection with members of the miR-200 families relative to
negative controls. The results demonstrate that although
miR-200 family induced MET is generally correlated
with a significant increase in sensitivity to cisplatin,
significant variation exists among individual family
members. In this case, the variability was associated
with sequence variation mapping to the non-seed re-
gion of individual family members.Conclusions
Collectively our results are consistent with earlier find-
ings from our lab [8] and others [9,10] indicating that
members of the miR-200 family are involved in EMT/
MET and OC metastasis. Our results also indicate that
significant variation exists among family members in the
regulation of molecular processes underlying specific
features of the EMT/MET process and that this variation
is associated with sequence variation mapping to both
the seed and non-seed region of individual family mem-
bers. Our results generally support the notion that ex-
ogenous modulations in the expression of miRNAs
involved in EMT may serve as the basis of importantnew strategies in the treatment of ovarian and other
types of cancer [32].
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